Matches in Nanopublications for { ?s ?p "[Combined neoadjuvant trastuzumab and docetaxel induced high clinical response rates for HER2-overexpressing breast cancer, in particular for inflammatory breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP562168.RAZcFWZxLuy8Y9qrxOOBXRhGPUekTIao9KV7hTrHGcjGE130_assertion description "[Combined neoadjuvant trastuzumab and docetaxel induced high clinical response rates for HER2-overexpressing breast cancer, in particular for inflammatory breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP562168.RAZcFWZxLuy8Y9qrxOOBXRhGPUekTIao9KV7hTrHGcjGE130_provenance.
- assertion description "[Combined neoadjuvant trastuzumab and docetaxel induced high clinical response rates for HER2-overexpressing breast cancer, in particular for inflammatory breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Combined neoadjuvant trastuzumab and docetaxel induced high clinical response rates for HER2-overexpressing breast cancer, in particular for inflammatory breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Combined neoadjuvant trastuzumab and docetaxel induced high clinical response rates for HER2-overexpressing breast cancer, in particular for inflammatory breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP427413.RAegHWzxvYTOAeNJgReQWtF5KMEW9rzv-Xwpa6lMs6ur4130_assertion description "[Combined neoadjuvant trastuzumab and docetaxel induced high clinical response rates for HER2-overexpressing breast cancer, in particular for inflammatory breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP427413.RAegHWzxvYTOAeNJgReQWtF5KMEW9rzv-Xwpa6lMs6ur4130_provenance.
- NP427414.RAS_2dmwTzsbTmZ94CjB7-ntdk2ruKDMG7ofjE4-U2WK4130_assertion description "[Combined neoadjuvant trastuzumab and docetaxel induced high clinical response rates for HER2-overexpressing breast cancer, in particular for inflammatory breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP427414.RAS_2dmwTzsbTmZ94CjB7-ntdk2ruKDMG7ofjE4-U2WK4130_provenance.